Filtern
Gehört zur Bibliographie
- ja (50)
Erscheinungsjahr
Dokumenttyp
Sprache
- Englisch (50) (entfernen)
Schlagworte
- apoptosis (11)
- TNF (6)
- cell death (6)
- multiple myeloma (6)
- TNFR2 (5)
- TRAIL (5)
- Fn14 (4)
- TWEAK (4)
- CD40 (3)
- CD95 (3)
- NFκB (3)
- TNFR1 (3)
- TRAF2 (3)
- death receptors (3)
- Apoptosis (2)
- B cells (2)
- Expression (2)
- Factor receptor (2)
- NFkappaB (2)
- TNF receptor superfamily (2)
- TNF superfamily (2)
- Tumor-necrosis-factor (2)
- antibody (2)
- antibody fusion proteins (2)
- bone disease (2)
- cancer (2)
- cancer therapy (2)
- cancer treatment (2)
- caspase-8 (2)
- cells (2)
- cytokines (2)
- gene expression (2)
- inflammation (2)
- metastasis (2)
- necroptosis (2)
- necrotic cell death (2)
- positron emission tomography (2)
- regulatory T cells (2)
- 14.7K (1)
- ADHD (1)
- AMPK (1)
- Activation (1)
- Adrenocortical Carcinoma (1)
- Alpha therapy (1)
- Antikörper (1)
- Autoaggressionskrankheit (1)
- Autoimmune diseases (1)
- B cell receptors (1)
- BMP (1)
- Big Five (1)
- Biologika (1)
- Bioluminescence (1)
- Bone marrow transplantantation (1)
- Bone morphogenetic protein-2 (1)
- C1q/TNF related protein (CTRP) (1)
- CD27 (1)
- CD4+ T cell activation (1)
- CD40L (1)
- CD70 (1)
- CDH13 (1)
- CMV (1)
- CXCR4 (1)
- CXCR4/SDF-1 (1)
- CYP2C9 (1)
- CYP3A4 (1)
- CYR61 (1)
- Callyspongia siphonella (1)
- Cancer (1)
- CysLTR1 (1)
- Cysteine‐Rich Domain (CRD) (1)
- Cytokine (1)
- Cytotoxischer Antikörper (1)
- E3 14.7-kilodalton protein (1)
- FAS (1)
- FDG PET/CT (1)
- Factor-alpha (1)
- FcγR receptor (1)
- GVHD (1)
- Graft-versus-host disease (1)
- Graft-versus-leukemia (1)
- GvHD (1)
- HT29 cells (1)
- HaCaT cells (1)
- Hematopoietic cell transplantation (1)
- Immuntherapie (1)
- Inhibitor (1)
- Ki67 (1)
- LC-HRESIMS (1)
- Leukämie (1)
- MDSC (1)
- MPI (1)
- MPS (1)
- Mechanisms (1)
- Myofibroblast differentiation (1)
- NF-Kappa-B (1)
- NF-kappa-B (1)
- NFkB (1)
- Nekrose (1)
- PRRT (1)
- Polymorphisms (1)
- Pre‐Ligand Assembly Domain (PLAD) (1)
- Proliferation (1)
- Promoter (1)
- RAF1 (1)
- Receptor (1)
- Regulatory-cells (1)
- Rhabdomyosarkom (1)
- Rheumatoid arthritis (1)
- Ruxolitinib (1)
- Signaltransduktion (1)
- Single‐Molecule Localization Microscopy (SMLM) (1)
- Smooth-muscle-cells (1)
- Suppression (1)
- T cells (1)
- TGF-beta (1)
- TNF ligand superfamily (1)
- TNF receptor (TNFR) family (1)
- TNF receptor 2 (TNFR2) (1)
- TNF receptor associated factor 1 and 2 (TRAF1, TRAF2) (1)
- TNFR family costimulatory receptors (1)
- TNFR2 agonists (1)
- TNFR2 antagonism (1)
- TRAF1 (1)
- TRAILR1 (1)
- TRAILR2 (1)
- Transcription (1)
- Transplantat-Wirt-Reaktion (1)
- Tregs (regulatory T cells) (1)
- Tumor-Nekrose-Faktor (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{18}\)F-FDG PET/CT (1)
- accuracy (1)
- acute (1)
- acute ischemic stroke (1)
- adalimumab (1)
- adiponectin (1)
- agonist (1)
- agonistic antibodies (1)
- agreeableness (1)
- alkaloids (1)
- amphibian skin secretions (1)
- anakinra (1)
- anti-TNFRSF receptor (TNFR) antibodies (1)
- antibacterial (1)
- antibiofilm (1)
- antibody engineering (1)
- antibody fusion protein (1)
- anticancer (1)
- anticancer activity (1)
- antimicrobial peptides (1)
- antitrypanosomal (1)
- anurans (1)
- aryl hydrocarbon receptor (AhR) (1)
- atherosclerosis (1)
- autoimmune disease (1)
- autologous transplantation (1)
- benzo[a]pyrene (1)
- binding (1)
- bispecific antibodies (1)
- bispezifische antikörper (1)
- blood coagulability (1)
- cancer immunotherapy (1)
- capecitabine (1)
- cardiogenic (1)
- cardiovascular disease (1)
- case report (1)
- cell binding (1)
- cell cycle and cell division (1)
- cell metabolism (1)
- cell proliferation (1)
- cell staining (1)
- cell therapy (1)
- cell viability testing (1)
- chemokine receptor (1)
- closed-loop systems (1)
- colorectal cancer (1)
- compartmentalization (1)
- costimulation (1)
- crosslinked coating (1)
- curative resection (1)
- cytokine storm (1)
- dendritic cells (1)
- dendrobates pumilio (1)
- dermatitis (1)
- designer cell (1)
- drug-delivery (1)
- ejection fraction (1)
- enbrel (1)
- encephalitis (1)
- esophagogastric junction (1)
- etanercept (1)
- executive functions (1)
- experience (1)
- extracorporeal membrane oxygenation (1)
- feasibility (1)
- formicidae (1)
- gene network (1)
- graft versus host disease (1)
- graft vs. host disease (1)
- growth-factor receptor (1)
- hepatic resection (1)
- human keratinocytes (1)
- hymenoptera (1)
- imaging agents (1)
- imaging techniques (1)
- immune cells (1)
- immune regulation (1)
- immunotherapy (1)
- in vitro (1)
- in vivo imaging (1)
- increased risk (1)
- inhibitor (1)
- involvement (1)
- ischemic stroke (1)
- leukemia (1)
- liver resection (1)
- lung resection (1)
- magnetic properties (1)
- malignancies (1)
- management (1)
- mediated apoptosis (1)
- membrane receptor signaling (1)
- metabolism (1)
- metabolomic profiling (1)
- mice impact (1)
- microenvironment (1)
- microhylidae (1)
- mitochondrial dysfunction (1)
- molecular imaging (1)
- molecular medicine (1)
- motor cortex (1)
- mutualisms (1)
- myeloid (1)
- myosin-VI (1)
- nanoparticles (1)
- neurodevelopment (1)
- oral anticancer drugs (1)
- oxindole alkaloids (1)
- p100 (1)
- paltothyreus tarsatus (1)
- pathways (1)
- patient-doctor-relationship (1)
- peptide receptor (1)
- phosphorylation (1)
- point-of-care echocardiography (1)
- polymorphisms inflammation (1)
- prognosis (1)
- progression (1)
- pyrazolo[3,4-d]pyrimidine (1)
- radionuclide therapy (1)
- receptor cluster (1)
- regulatory T cell (1)
- regulatory T-cell (Treg) (1)
- rekombinante Antikörper (1)
- retrospective study (1)
- rheumatoid arthritis (1)
- ripk1 (1)
- ripk3 (1)
- sarcoidosis (1)
- scFv (1)
- septic (1)
- serum retention (1)
- shock (1)
- signal inhibition (1)
- signal transduction (1)
- signaling (1)
- skin (1)
- small interfering RNAs (1)
- somatostatin receptors (1)
- stem-cell transplantation (1)
- stroke unit (1)
- suppressor cells (1)
- surface modification (1)
- surgical oncology (1)
- surgical resection (1)
- survival (1)
- survival analysis (1)
- synthetic biology (1)
- systolic dysfunction (1)
- tetraparesis (1)
- therapeutic drug monitoring (1)
- tisindoline (1)
- toxicity (1)
- treatment response (1)
- tumor necrosis factor (1)
- tumor necrosis factor (TNF) (1)
- von Willebrand factor (1)
- working memory (1)
Institut
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (50) (entfernen)
Sonstige beteiligte Institutionen
Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
Cancer cells frequently escape from immune surveillance by down-regulating two important components of the immune defence: antigen-presenting MHC and costimulatory molecules. Therefore several novel anti-tumour compounds that aim to assist the immune system in recognising and fighting cancer are currently under development. Recombinant bispecific antibodies represent one group of such novel therapeutics. They target two different antigens and recruit cytotoxic effector cells to tumour cells. For cancer immunotherapy, bispecific T cell-engaging antibodies are already well characterised. These antibodies target a tumour-associated antigen and CD3ε, the constant molecule of the T cell receptor complex.
On the one hand, this study presents the development of a bispecific antibody targeting CD3ε and the rhabdomyosarcoma-associated fetal acetylcholine receptor. On the other hand, it describes a novel two-part trispecific antibody format for the treatment of leukaemia and other haematological malignancies in the context of haematopoietic stem cell transplantation (HSCT).
For HSCT, an HLA-identical donor is preferred, but very rarely available. In an HLA-mismatched setting, the HLA disparity could be exploited for targeted cancer treatment. In the present study, a two-part trispecific HLA-A2 × CD45 × CD3 antibody was developed for potential cases in which the patient is HLA-A2-positive, but the donor is not. This holds true for about half the cases in Germany, since HLA-A2 is the most common HLA molecule found here. Combinatorial targeting of HLA-A2 and the leucocyte-common antigen CD45 allows for highly specific dual-antigen restricted tumour targeting.
More precisely, two single-chain antibody constructs were developed: i) a single-chain variable fragment (scFv) specific for HLA-A2, and ii) a scFv against CD45, both linked to the VL and the VH domain of a CD3ε-specific antibody, respectively. It turned out that, after the concomitant binding of these constructs to the same HLA-A2- and CD45-expressing cell, the unpaired variable domains of a CD3ε-specific antibody assembled to a functional scFv. In a therapeutic situation, this assembly should exclusively occur on the recipient’s blood cancer cells, leading to T cell-mediated cancer cell destruction. In this way, a relapse of disease might be prevented, and standard therapy (radiation and chemotherapy) might be omitted.
For both approaches, the antibody constructs were periplasmically expressed in E. coli, purified via His tag, and biochemically characterised. Their binding to the respective targets was proven by flow cytometry. The stimulatory properties of the antibodies were assayed by measuring IL-2 release after incubation with T cells and antigen-expressing target cells. Both the bispecific antibody against rhabdomyosarcoma and the assembled trispecific antibody against blood cancer mediated T-cell activation in a concentration-dependent manner at nanomolar concentrations. For the trispecific antibody, this effect indeed proved to be dual antigen-restricted, as it could be blocked by prior incubation of either HLA-A2- or CD45-specific scFv and did not occur on single-positive (CD45+) or double-negative (HLA-A2- CD45-) target cells. Furthermore, antibodies from both approaches recruited T cells for tumour cell destruction in vitro.
Background:
Metastatic Adrenocortical Carcinoma (ACC) is a rare malignancy with a poor 5-year-survival rate (<15%). A surgical approach is recommended in selected patients if complete resection of distant metastasis can be achieved. To date there are only limited data on the outcome after surgical resection of hepatic metastases of ACC.
Methods:
A retrospective analysis of the German Adrenocortical Carcinoma Registry was conducted. Patients with liver metastases of ACC but without extrahepatic metastases or incomplete tumour resection were included.
Results:
Seventy-seven patients fulfilled these criteria. Forty-three patients underwent resection of liver metastases of ACC. Complete tumour resection (R0) could be achieved in 30 (69.8%). Median overall survival after liver resection was 76.1 months in comparison to 10.1 months in the 34 remaining patients with unresected liver metastases (p < 0.001). However, disease free survival after liver resection was only 9.1 months. Neither resection status (R0/R1) nor extent of liver resection were significant predictive factors for overall survival. Patients with a time interval to the first metastasis/recurrence (TTFR) of greater than 12 months or solitary liver metastases showed significantly prolonged survival.
Conclusions:
Liver resection in the case of ACC liver metastases can achieve long term survival with a median overall survival of more than 5 years, but disease free survival is short despite metastasectomy. Time to recurrence and single versus multiple metastases are predictive factors for the outcome.
Soluble tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK), in contrast to membrane TWEAK and TNF, is only a weak activator of the classical NFκB pathway. We observed that soluble TWEAK was regularly more potent than TNF with respect to the induction of TNF receptor-associated factor 1 (TRAF1), a NFκB-controlled signaling protein involved in the regulation of inflammatory signaling pathways. TNF-induced TRAF1 expression was efficiently blocked by inhibition of the classical NFκB pathway using the IKK2 inhibitor, TPCA1. In contrast, in some cell lines, TWEAK-induced TRAF1 production was only partly inhibited by TPCA1. The NEDD8-activating enzyme inhibitor MLN4924, however, which inhibits classical and alternative NFκB signaling, blocked TNF- and TWEAK-induced TRAF1 expression. This suggests that TRAF1 induction by soluble TWEAK is based on the cooperative activity of the two NFκB signaling pathways. We have previously shown that oligomerization of soluble TWEAK results in ligand complexes with membrane TWEAK-like activity. Oligomerization of soluble TWEAK showed no effect on the dose response of TRAF1 induction, but potentiated the ability of soluble TWEAK to trigger production of the classical NFκB-regulated cytokine IL8. Transfectants expressing soluble TWEAK and membrane TWEAK showed similar induction of TRAF1 while only the membrane TWEAK expressing cells robustly stimulated IL8 production. These data indicate that soluble TWEAK may efficiently induce a distinct subset of the membrane TWEAK-targeted genes and argue again for a crucial role of classical NFκB pathway-independent signaling in TWEAK-induced TRAF1 expression. Other TWEAK targets, which can be equally well induced by soluble and membrane TWEAK, remain to be identified and the relevance of the ability of soluble TWEAK to induce such a distinct subset of membrane TWEAK-targeted genes for TWEAK biology will have to be clarified in future studies.
Donor CD4\(^+\)Foxp3\(^+\) regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist before allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2-and T reg cell-dependent manner. The beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A corresponding human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strategy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.
Multiple activities are ascribed to the cytokine tumor necrosis factor (TNF) in health and disease. In particular, TNF was shown to affect carcinogenesis in multiple ways. This cytokine acts via the activation of two cell surface receptors, TNFR1, which is associated with inflammation, and TNFR2, which was shown to cause anti-inflammatory signaling. We assessed the effects of TNF and its two receptors on the progression of pancreatic cancer by in vivo bioluminescence imaging in a syngeneic orthotopic tumor mouse model with Panc02 cells. Mice deficient for TNFR1 were unable to spontaneously reject Panc02 tumors and furthermore displayed enhanced tumor progression. In contrast, a fraction of wild type (37.5%), TNF deficient (12.5%), and TNFR2 deficient mice (22.2%) were able to fully reject the tumor within two weeks. Pancreatic tumors in TNFR1 deficient mice displayed increased vascular density, enhanced infiltration of CD4+ T cells and CD4+ forkhead box P3 (FoxP3)+ regulatory T cells (Treg) but reduced numbers of CD8+ T cells. These alterations were further accompanied by transcriptional upregulation of IL4. Thus, TNF and TNFR1 are required in pancreatic ductal carcinoma to ensure optimal CD8+ T cell-mediated immunosurveillance and tumor rejection. Exogenous systemic administration of human TNF, however, which only interacts with murine TNFR1, accelerated tumor progression. This suggests that TNFR1 has basically the capability in the Panc02 model to trigger pro-and anti-tumoral effects but the spatiotemporal availability of TNF seems to determine finally the overall outcome.
In the present study, LC-HRESIMS-assisted dereplication along with bioactivity-guided isolation led to targeting two brominated oxindole alkaloids (compounds 1 and 2) which probably play a key role in the previously reported antibacterial, antibiofilm, and cytotoxicity of Callyspongia siphonella crude extracts. Both metabolites showed potent antibacterial activity against Gram-positive bacteria, Staphylococcus aureus (minimum inhibitory concentration (MIC) = 8 and 4 µg/mL) and Bacillus subtilis (MIC = 16 and 4 µg/mL), respectively. Furthermore, they displayed moderate biofilm inhibitory activity in Pseudomonas aeruginosa (49.32% and 41.76% inhibition, respectively), and moderate in vitro antitrypanosomal activity (13.47 and 10.27 µM, respectively). In addition, they revealed a strong cytotoxic effect toward different human cancer cell lines, supposedly through induction of necrosis. This study sheds light on the possible role of these metabolites (compounds 1 and 2) in keeping fouling organisms away from the sponge outer surface, and the possible applications of these defensive molecules in the development of new anti-infective agents.
Targeted cancer therapy concepts often aim at the induction of adjuvant antitumor immunity or stimulation of tumor cell apoptosis. There is further evidence that combined application of immune stimulating and tumor apoptosis-inducing compounds elicits a synergistic antitumor effect. Here, we describe the development and characterization of bifunctional fusion proteins consisting of a single-chain variable fragment (scFv) domain derived from the CD40-specific monoclonal antibody G28-5 that is fused to the N-terminus of stabilized trimeric soluble variants of the death ligand TNF-related apoptosis-inducing ligand (TRAIL). As shown before by us and others for other cell surface antigen-targeted scFv-TRAIL fusion proteins, scFv:G28-TRAIL displayed an enhanced capacity to induce apoptosis upon CD40 binding. Studies with scFv:G28 fusion proteins of TRAIL mutants that discriminate between the two TRAIL death receptors, TRAILR1 and TRAILR2, further revealed that the CD40 binding-dependent mode of apoptosis induction of scFv:G28-TRAIL is operable with each of the two TRAIL death receptors. Binding of scFv:G28-TRAIL fusion proteins to CD40 not only result in enhanced TRAIL death receptor signaling but also in activation of the targeted CD40 molecule. In accordance with the latter, the scFv:G28-TRAIL fusion proteins triggered strong CD40-mediated maturation of dendritic cells. The CD40-targeted TRAIL fusion proteins described in this study therefore represent a novel type of bifunctional fusion proteins that couple stimulation of antigen presenting cells and apoptosis induction.
Purpose:
The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients’ adherence to therapy. Aspects of a close patient–doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce.
Patients and methods:
Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient–Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients’ perceptions and behavior. Medical data were extracted from the charts.
Results:
Non-adherence was reported by 20% of the 64 participants. The perceived quality of the patient–doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808–1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95% CI=1.090–1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95% CI=1.010–1.551) were predictors of adherence and the quality of the patient–doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life.
Conclusions:
In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients’ informational needs as well as the associations of patients’ beliefs and satisfaction about the information received suggest a benefit from a trustful patient–doctor relationship.
The current treatment strategies for diseases are assessed on the basis of diagnosed phenotypic changes due to an accumulation of asymptomatic events in physiological processes. Since a diagnosis can only be established at advanced stages of the disease, mainly due to insufficient early detection possibilities of physiological disorders, doctors are forced to treat diseases rather than prevent them. Therefore, it is desirable to link future therapeutic interventions to the early detection of physiological changes. So-called sensor-effector systems are designed to recognise disease-specific biomarkers and coordinate the production and delivery of therapeutic factors in an autonomous and automated manner. Such approaches and their development are being researched and promoted by the discipline of synthetic biology, among others.
Against this background, this paper focuses on the in vitro design of cytokine-neutralizing sensor-effector cells designed for the potential treatment of recurrent autoimmune diseases, especially rheumatoid arthritis.
The precise control of inducible gene expression was successfully generated in human cells. At first, a NF-κB-dependent promoter was developed, based on HIV-1 derived DNA-binding motives. The activation of this triggerable promoter was investigated using several inducers including the physiologically important NF-κB inducers tumor necrosis factor alpha (TNFα) and interleukin 1 beta (IL-1β). The activation strength of the NF-κB-triggered promoter was doubled by integrating a non-coding RNA. The latter combined expressed RNA structures, which mimic DNA by double stranded RNAs and have been demonstrated to bind to p50 or p65 by previous publications. The sensitivity was investigated for TNFα and IL-1β. The detection limit and the EC50 values were in in the lower picomolar range. Besides the sensitivity, the reversibility and dynamic of the inducible system were characterized. Hereby a close correlation between pulse times and expression profile was shown.
The optimized NF-κB-dependent promoter was then coupled to established TNFα- and IL-1-blocking biologicals to develop sensor-effector systems with anti-inflammatory activity, and thus potential use against autoimmune diseases such as rheumatoid arthritis. The biologicals were differentiated between ligand-blocking and receptor-blocking biologicals and different variants were selected: Adalimumab, etanercept and anakinra. The non-coding RNA improved again the activation strength of NF-κB-dependent expressed biologicals, indicating its universal benefit. Furthermore, it was shown that the TNFα-induced expression of NF-κB-regulated TNFα-blocking biologics led to an extracellular negative feedback loop. Interestingly, the integration of the non-coding RNA and this negative feedback loop has increased the dynamics and reversibility of the NF-κB-regulated gene expression. The controllability of drug release can also be extended by the use of inhibitors of classical NF-κB signalling such as TPCA-1. The efficacy of the expressed biologicals was detected through neutralization of the cytokines using different experiments. For future in vivo trials, first alginate encapsulations of the cells were performed. Furthermore, the activation of NF-κB-dependent promoter was demonstrated using co-cultures with human plasma samples or using synovial liquids.
With this generated sensor-effector system we have developed self-adjusting cytokine neutralizer cells as a closed-loop delivery system for anit-inflammatory biologics.